JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M201648200 on June 21, 2002

J. Biol. Chem., Vol. 277, Issue 35, 31734-31739, August 30, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/35/31734    most recent
M201648200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, W.-S.
Right arrow Articles by Chang, K.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, W.-S.
Right arrow Articles by Chang, K.-S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Promyelocytic Leukemia Protein Represses A20-mediated Transcription*

Wen-Shu Wu, Zhi-Xiang Xu, and Kun-Sang ChangDagger

From the Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Received for publication, February 18, 2002, and in revised form, June 20, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The promyelocytic leukemia (PML) protein is a tumor suppressor that is disrupted by the chromosomal translocation t(15;17), a consistent cytogenetic feature of acute promyelocytic leukemia. A role of PML in multiple pathways of apoptosis was conclusively demonstrated using PML-/- animal and cell culture models. In a previous study, we found that PML sensitizes tumor necrosis factor-induced apoptosis in tumor necrosis factor (TNF)-resistant U2OS cells. This finding helped to explain the mechanism of PML-induced apoptosis. The zinc finger protein A20 is a target gene of NFkappa B inducible by TNFalpha , and it is a potent inhibitor of TNF-induced apoptosis. In the this study, we demonstrated that PML is a transcriptional repressor of the A20 promoter and that PML represses A20 expression induced by TNFalpha . We showed that PML inhibits A20 transactivation through the NFkappa B site by interfering with its binding to the promoter. We also showed that stable overexpression of A20 inhibits apoptosis and caspase activation induced by PML/TNFalpha . The results of this study suggest that A20 is a downstream target of PML-induced apoptosis and supports a role of A20 in modulating cell death induced by PML/TNFalpha in TNF-resistant cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The disruption of the promyelocytic leukemia (PML)1 gene by the t(15;17) chromosomal translocation is believed to play an important role in the pathogenesis of acute promyelocytic leukemia (APL) (1). PML is a multifunctional Ring finger protein normally localized within the nucleus as a macromolecular structure in a nuclear speckled pattern designated PML nuclear body (NB) or PML oncogenic domain (2). In APL cells, the normal PML NBs are disrupted as a result of forming heterodimer with the fusion protein PML-retinoic acid receptor alpha  to form a nuclear microspeckled pattern. Interestingly, all-trans-retinoic acid treatment of APL patients induced dramatic differentiation of the leukemia blasts associated with rapid degradation of PML-retinoic acid receptor alpha  and reorganization of the normal PML NB that presumably restore normal PML function (2). PML has been shown to be a cellular growth and tumor suppressor (3-5) by acting as a regulator of apoptosis (6, 7) and cell-cycle progression (4, 5). The expression of PML suppresses transformation by cooperative oncogenes of mouse embryo fibroblasts and inhibits the neu-induced growth and tumorigenicity of NIH3T3 cells and many cancer cell lines (1, 2, 8). Wang et al. (6) recently showed that PML plays a critical role in multiple pathways of apoptosis. Studies using a PML knock-out animal model demonstrated that PML is essential for apoptosis induced by TNFalpha , ceramide, gamma -irradiation, interferons, and Fas (6). However, the mechanism by which PML induces apoptosis remains obscure. The PML protein is normally modified by SUMO-1, a small ubiquitin-like protein, at three different sites (9). SUMO-1 modification plays an essential role in the formation of PML NB and in its function in transcriptional regulation and apoptosis (10).

PML also functions as a transcriptional regulator (for review see Refs. 11 and 12). The transcription coactivator CREB-binding protein, a histone acetyltransferase, interacts with PML and colocalizes in the PML NB, suggesting a role of PML in mediating transcription (13, 14). The highly acetylated chromatin presumably associated with actively transcribing genes was also found to be associated with PML NB (14). Moreover, PML has been shown to upregulate the transcription of genes related to the major histocompatibility complex (15), GATA-2 (16), AP-1 (17), and p53-mediated transcriptions (18-20). On the other hand, when PML was fused downstream of the GAL4 DNA binding domain, it repressed GAL4-mediated transcription through a mechanism that is sensitive to trichostatin A, a specific inhibitor of the transcription corepressor histone deacetylases (21, 22). PML has been shown to interact with histone deacetylases (22, 23) and repress transcription by deacetylation of the target promoter (22). Another mechanism of transcription repression by PML was also reported recently. It was found that PML interacts directly with transcription factor Sp1 and interferes with its ability to bind DNA, leading to repression of the Sp1-dependent transcription of epidermal growth factor receptor promoter (24).

A20 is a target gene of NFkappa B and was originally identified as a zinc finger protein induced by treatment with TNFalpha (25). A20 was characterized as a potent inhibitor of TNF-induced apoptosis (26). The overexpression of A20 significantly downregulated NFkappa B activation and inhibited the expression of NFkappa B target genes, indicating that A20 is a potent inhibitor of NFkappa B (27, 28). Together, these findings suggest that A20 plays a role as a negative feedback regulator of NFkappa B activation. The recent finding that A20-deficient mice failed to regulate TNF-induced NFkappa B activation and apoptosis supports this notion (29). This finding implies that A20 plays a critical role in mediating apoptosis and inflammation by terminating the TNF-induced NFkappa B responses.

To further understand the mechanism of how PML induces apoptosis, our present study shows that PML significantly inhibits the expression of A20, a potent repressor of TNF-induced apoptosis. PML represses the A20 promoter induced by TNFalpha and phorbol 12-myristate 13-acetate (PMA) through the NFkappa B site. Our study further shows that A20 inhibits apoptosis induced by PML/TNFalpha and explains the mechanism by which PML induces apoptosis by sensitizing the TNF death receptor pathway.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmids Construction-- The inducible expression plasmid pMEP4/PML was constructed by subcloning the full-length PML cDNA (PML3) into the NotI/XhoI sites of the pMEP4 vector (Invitrogen). pMEP4/HA-A20 was constructed by cloning the polymerase chain reaction-amplified full-length A20 cDNA into the EcoRI site of the pCruz/HA vector to generate pCruz/HA-A20. The HA-A20 fragment was then excised by XhoI/BglII and subcloned into the pMEP4 vector. The A20 promoter-luciferase reporter construct A20PR-Luc was generated by cloning the PCR-amplified fragment of the A20 promoter using the upstream primer 5'-CCCAGCCCGACCCAGAGAGTCACGTGAC-3' and the downstream primer 5'-CCCAGACTGCGCAGTCTGCTTTGCCCCG-3' and inserting them into the pGL3 vector (Promega, Madison, WI). Correct DNA sequence of all plasmids was confirmed by direct DNA sequencing.

Cell Culture and Reagents-- The U2OS cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Anti-HA monoclonal antibody was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-caspase-7 antibody (number 66871A) was purchased from PharMingen. Anti-A20 antibody (number 40901) was obtained from Active & Motif, Inc. (Carlsbad, CA).

Transfection and Luciferase Reporter Assay-- Cells were cultured to semiconfluence and transfected with the expression plasmids using FuGENE 6 transfection reagent (Roche Diagnostics). Luciferase activity was determined using the luciferase reporter assay according to the manufacturer's protocol (Promega).

Generation of Stable Cell Lines-- U2OS cells were transfected with each of the following plasmids: pMEP4 (negative control), pMEP4/HA-A20, and pMEP4/PML with FuGENE 6 reagent. Cells were then selected with hygromycin (200 µg/ml) for 10 days. Pools of hygromycin-resistant stable clones were selected. Inducible expression of the respective proteins in these stable cell lines was determined by induction with CdSO4 (5 µM) for 20 h followed by immunofluorescent staining and Western blot analysis. Cell death was examined by trypan blue exclusion assay.

RNA Preparation and cDNA Synthesis-- Total RNA was prepared from cells using RNeasy mini-kit (Qiagen). cDNA was synthesized from 4 µg of total RNA using the Superscript preamplification system obtained from Invitrogen.

Preparation of Nuclear Proteins-- Cultured cells were washed twice with cold phosphate-buffered saline and resuspended in ice-cold digitonin extraction buffer (10 mM PIPES, pH 6.8, 0.015% (w/v) digitonin, 300 mM NaCl, 3 mM MgCl2, 5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride). Cells were permeabilized for 10 min, assessed by trypan blue exclusion assay, and centrifuged for 5 min at 480 × g at 4 °C. The supernatant contains the cytoplasmic protein. The digitonin-insoluble pellet was resuspended in ice-cold Triton X-100 extraction buffer (10 mM PIPES, pH 7.4, 0.5% (v/v) Triton X-100, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride) and incubated on ice for 30 min. The nuclei were pelleted by centrifugation for 10 min at 5000 × g and resuspended in nuclear extraction buffer (50 mM PIPES, pH 7.5, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 0.5% (v/v) Nonidet P-40, and 10% (v/v) glycerol). The nuclear mixture was incubated for 30 min on ice and then centrifuged for 5 min (6780 × g) at 4 °C. The supernatant contains the nuclear proteins.

Electrophoretic Mobility Shift Assay-- The in vitro-translated PML or p65 proteins were synthesized by the TnT-coupled wheat germ translation system (Promega). Nuclear extracts were prepared from U2OS stable cell lines or cells treated with TNFalpha (20 ng/ml) for 1 h. The A20 promoter NFkappa B probe was prepared by annealing the oligonucleotides 5'-GACTTTGGAAAGTCCCGTGGAAATCCCCGGG-3' and 5'-GGCCCGGGGATTTCCACGGGACTTTCCAAAGT-3', and the 3'-recessive ends were labeled with Klenow fragment fill-in reaction. Binding reactions contained 5 µg of nuclear extracts, 1 µg of poly(dI-dC), and 1 ng of NFkappa B probe (1 × 105 cpm) in 20 µl of KCl binding buffer (10% glycerol, 1 mM EDTA, 5 mM KCl, 5 mM dithiothreitol, and 20 mM Tris-HCl, pH 8.0). The reaction was incubated for 20 min at room temperature and then resolved in a 5% polyacrylamide gel in Tris-glycine buffer (50 mM Tris, 0.4 M glycine, and 2 mM EDTA, pH 8.5). For competition or supershift assays, 50 ng of unlabeled probe or 1 µg of anti-p65 monoclonal antibody, respectively, was added to the binding reactions.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PML Inhibits Upregulation of A20 Induced by TNFalpha -- Our preliminary study showed that PML significantly sensitized TNF-induced apoptosis in the TNF-resistant cell line U2O. To understand the effects of PML on the TNF-induced apoptotic pathway, we investigated the effect of PML on the expression of A20 in the osteosarcoma cell line U2OS. We found that TNFalpha induces a significant increase in A1 and A20 expression in these cells but not c-FLIP (Fig. 1a). To examine the effects of PML on the expression of A20, stable clones of inducible PML in U2OS cells (U2OS/PML) and the control U2OS cells (pMEP4/U2OS) were established. These cells were treated with 5 µM cadmium sulfate to induce PML expression followed by the treatment of TNFalpha . The results of this study showed that expression of PML significantly repressed the expression of A20 induced by TNFalpha (Fig. 1b). No such effect on A20 expression was found in the control cell line pMEP4/U2OS or in the PML/U2OS cells if Cd2+ was not included in the culture medium to induce PML expression. This study suggests that PML is a specific inhibitor of A20 expression.


View larger version (43K):
[in this window]
[in a new window]
  		Fig. 1.   Repression of A20 expression by PML in U2OS cells. a, A1 and A20 are inducible by TNFalpha in U2OS cells. U2OS cells were starved for 2 h in Dulbecco's modified Eagle's medium with 05% serum and then treated (or untreated) with 20 ng/ml TNFalpha for 2 h. Total RNA in these cells was isolated, and PCR was performed for 22 cycles with specific primer pairs. b, PML inhibits upregulation of A20 induced by TNFalpha . Stable cell lines pMEP4/U2OS (control) and PML/U2OS were treated (or untreated) with 5 µM Cd2+ for 20 h to induce PML expression and then cultured in Dulbecco's modified Eagle's medium with 0.5% serum in the presence or absence of 20 ng/ml TNFalpha for another 6 h. Total protein was isolated and subjected to Western blotting using specific antibodies against A20, PML, and alpha -tubulin.

PML Represses the Promoter Activity of A20 Induced by TNFalpha -- To continue to investigate the effects of PML on A20 expression, the A20 promoter-luciferase construct (pA20PR-Luc) was created and used in a series of cotransfection experiments to investigate whether PML affects the transactivation of the A20 promoter. We first investigated the effects of PML expression on TNFalpha -induced activation of the A20 promoter. In the cotransfection experiments, U2OS cells were transiently transfected with pcDNA3/PML or pcDNA3 and pA20PR-Luc. After 24 h, cells were treated with TNFalpha for 2 and 4 h. The results of this study presented in Fig. 2a demonstrate that the presence of PML significantly represses A20 promoter activity. A similar experiment was performed using the stable PML/U2OS cells and the control pMEP4/U2OS cells transfected with pA20PR-Luc followed by treatment with PMA. This experiment further showed that PML significantly represses transactivation of the A20 promoter in PML/U2OS cells treated with Cd2+ (Fig. 2b). No inhibitory effects of the A20 promoter were found in pMEP4/U2OS control and PML/U2OS cells not treated with Cd2+. These results demonstrated that PML represses the promoter activity of A20 induced by treatment with TNFalpha and PMA.


View larger version (50K):
[in this window]
[in a new window]
  		Fig. 2.   PML inhibits A20 promoter activity induced by TNFalpha and PMA. a, U2OS cells were cotransfected with A20PR-Luc reporter (0.2 µg) and pCDNA3/PML (0.8 µg) or pCDNA3 (0.58 µg) in 12-well plates. After 24 h, cells were treated with 20 ng/ml TNFalpha for the indicated times. Total proteins were isolated, and luciferase activity was determined using the luciferase assay kit (Promega). b, PML/U2OS and pMEP4/U2OS stable cells induced or uninduced with 5 µM Cd2+ were transfected with A20PR-Luc reporter plasmid. After 24 h, cells were treated with 10 ng/ml PMA for the indicated times. Luciferase activity was determined as described above. The expression plasmid pCMV/beta -galactosidase was included in each transfection assay to normalize transfection efficiencies.

PML Inhibits Transcriptional Activation of the A20 Promoter-- A20 is a downstream target gene of NFkappa B inducible by TNF treatment. Therefore, we speculate that PML represses transcription of A20 through the inhibition of the NFkappa B function. To test this hypothesis, a series of cotransfection experiments was performed with pA20PR-Luc in the presence of RelA/p65 expression plasmid and increasing concentrations of pcDNA/PML. The results presented in Fig. 3 demonstrate that the presence of RelA/p65 dramatically activated the promoter activity of A20. Cotransfection with pcDNA3/PML at increasing concentrations significantly repressed A20 promoter activity in a dose-dependent manner. This result indicates that PML represses the RelA/p65-dependent transactivation of the A20 promoter.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 3.   PML inhibits A20 promoter activity through NFkappa B sites. U2OS cells were cotransfected with A20PR-Luc reporter (0.2 µg), pCDNA3/p65 (0.05 µg), and the indicated amount of pCDNA3/PML in 12-well plates. An equal molar of final DNA concentration in each cotransfection assay was adjusted by the addition of pcDNA3 plasmid. After 24 h, total protein was isolated, and luciferase activity was determined. The expression plasmid pCMV/beta -galactosidase was included in each transfection to normalize transfection efficiencies.

PML Interferes with NFkappa B Binding to the A20 Promoter-- The study described above suggests that PML represses RelA-dependent transactivation by interfering with NFkappa B binding to the A20 promoter. To further understand how PML represses transactivation of the A20 promoter through NFkappa B, electrophoretic mobility shift assay was performed using nuclear protein isolated from stable inducible cell lines pMEP4/U2OS and PML/U2OS treated or untreated with TNFalpha . In this assay, electrophoretic mobility shift assay was performed using the DNA sequence derived from the NFkappa B site of the A20 promoter. The results presented in Fig. 4 demonstrate that the expression of PML inhibited the binding of p65/RelA to the consensus sequences (lanes 5 and 6). Together, these studies suggest that PML inhibits NFkappa B binding to the promoter of A20 and consequently represses its transactivation.


View larger version (78K):
[in this window]
[in a new window]
  		Fig. 4.   PML interferes with NFkappa B binding to A20 promoter. Nuclear extracts were isolated from the inducible stable cell lines pMEP4/U2OS and PML/U2OS pretreated with 5 µM Cd2+ for 20 h and activated with TNFalpha (20 ng/ml) for 20 min. electrophoretic mobility shift assay was performed using NFkappa B probe derived from the A20 promoter. SS, supershift.

Overexpression of A20 Inhibits Apoptosis Induced by PML/TNFalpha -- It is clear that A20 is a target gene of NFkappa B inducible by TNFalpha (25). There is also an abundance of evidence to suggest that A20 acts as a potent inhibitor of NFkappa B (27-29). This raises the possibility that A20 plays an important role as a negative feedback regulator of NFkappa B functions. To investigate the possible functional interaction between PML and A20, we investigated whether the expression of A20 has any significant effects on PML/TNFalpha -induced apoptosis in U2OS cells. To address this question, a pool of inducible stable cell lines of A20 in U2OS cells driven by the metallothionine promoter was established. The expression of A20 can be induced by a low concentration of Cd2+ (Fig. 5a). A control cell line (pMEP4/U2OS) transfected with the empty vector alone was also established. The results presented in Fig. 5b show that a significant degree of cell death was induced after a 24-h infection with recombinant PML adenovirus (Ad-PML) and 8-h treatment with TNFalpha . However, PML/TNFalpha -induced cell death was significantly reduced in cells overexpressing A20, indicating that A20 inhibited apoptosis induced by PML/TNFalpha . The results shown in Fig. 5c demonstrate that control pMEP4/U2OS cells treated with PML/TNFalpha significantly activated procaspase-7; however, in cells overexpressing A20, procaspase-7 activation was significantly reduced. Thus, this study demonstrated that A20 inhibits cell death induced by PML/TNFalpha in TNF-resistant cells.


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 5.   Overexpression of A20 inhibits TNFalpha /PML induced apoptosis. a, inducible expression of A20 by Cd2+ in A20/U2OS stable cell line. A20/U2OS cells were treated with the indicated concentration of Cd2+ for 18 h, and total protein was isolated and subjected to Western blot analysis with anti-A20 and anti-tubulin antibodies. b and c, overexpression of A20 inhibits apoptosis induced by PML/TNFalpha . The inducible stable cell lines pMEP4/U2OS and A20/U2OS were treated (or untreated) with 5 µM Cd2+ and infected with Ad-C or Ad-PML (30). After 16 h, cells were treated (or untreated) with TNFalpha (20 ng/ml) and then allowed to continue culturing for another 8 h. Cell death was determined by trypan blue exclusion assay (b) and by caspase-7 (c) activation assay.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PML was originally cloned and characterized for its involvement in the nonrandom chromosomal translocation t(15;17), which occurs in ~99% of APL cases. The importance of PML in maintaining normal cellular function was unambiguously demonstrated by its essential role in multiple pathways of apoptosis (4, 5) and cell cycle progression (3, 6, 7). PML and PML NBs are induced by interferons and inflammatory stimuli (31-33), indicating that they have a role in response to inflammation and viral infection. PML is a cell growth and tumor suppressor; however, the mechanisms by which PML exerts its tumor suppressor function remains unclear. In MCF-7 cells, the overexpression of PML induced G1 cell-cycle arrest associated with an upregulation of p21, p53, cyclin D, and hypophosphorylation of the Rb (6). Unphosphorylated Rb binds the E2F transcription factor and limits its ability to activate the transcription of genes essential for the G1 to S transition (34).

PML does not bind DNA directly; however, it plays a role in transcriptional regulation through its association with the transcription coactivator CREB-binding protein and interacts with the transcription corepressor histone deacetylases (13, 14, 22). PML activates transcription by binding and sequestering the negative regulator, Daxx (35-37), interacting with p53 (18-20) and recruiting p53 to the PML NB to enhance transactivation of p53 target genes. PML also represses transcription by interacting with transcription factor Sp1 and interfering with its binding to the epidermal growth factor receptor promoter (24). The results presented in Fig. 4 suggest a similar mechanism of transcriptional repression by PML. In this case, PML represses transcription of the A20 gene by interfering with NFkappa B binding to the promoter. It is not clear why and how PML is involved in these two opposite functions in transcriptional regulation. Recent studies suggest that PML NB may serve as the storage site of important cellular regulatory proteins. Increased expression of PML may sequester these protein factors to the PML NBs and consequently limit their normal functional roles as a transcription activators or repressors.

Although a role of PML in multiple pathways of apoptosis has been clearly established, the molecular mechanisms remain unclear. PML is required for Daxx-induced apoptosis in mouse splenocytes. In the absence of PML, cellular localization of Daxx was altered, and its proapoptotic function was impaired (36). In these cells, the ability of Daxx to sensitize Fas-induced apoptosis was abrogated (36). Daxx was also shown to specifically enhance Fas-induced apoptosis (38) in human cells by association with PML NB through a mechanism that involved the activation of caspase 8 and caspase 3; however, it is not known what role PML plays in TNF-induced apoptosis.

The results presented in this report support the novel mechanism of PML-induced apoptosis in inhibiting the expression of A20, a potent inhibitor of TNF-induced apoptosis. This study showed that PML represses the promoter activity of A20 induced by treatment with TNFalpha and PMA. PML inhibits transactivation of the A20 promoter by interfering with NFkappa B binding to its consensus cis-acting element. This finding was further supported by the study showing that stable overexpression of A20 significantly inhibited apoptosis induced by the combined effects of PML and TNFalpha (Fig. 5). This study indicates that PML sensitizes TNFalpha -induced cell death by repressing the expression of A20 and inhibits its anti-apoptotic function.

A20 is a novel zinc finger protein first described as an early responsive gene inducible by TNF treatment (25). It was originally characterized as an inhibitor of TNF-induced apoptosis (26). A20 is also a potent inhibitor of NFkappa B activation induced by not only TNF but also by interleukin-1, lipopolysaccharide, PMA, and hydrogen peroxide (39). This inhibitory effect may be mediated through its interaction with tumor necrosis factor receptor-associated factors (40) or other A20 binding proteins (41). Interestingly, the expression of A20 is controlled by NFkappa B, suggesting that it is involved in a negative feedback mechanism in regulating NFkappa B. NFkappa B is an important transcription factor that regulates the expression of many mediators of inflammation (42) and anti-apoptotic proteins involved in the survival pathway (43, 44). The finding that PML represses the transcription of the A20 promoter by interfering with NFkappa B binding is interesting. It will be important to further investigate the mechanism by which PML inhibits the binding of NFkappa B to its target DNA sequence and to examine whether the two proteins are functionally associated in vivo.

    ACKNOWLEDGEMENT

We thank Vickie Williams for critical reading of the paper.

    FOOTNOTES

* This study was supported by National Institutes of Health Grant CA55577 (to K. S. C.). DNA sequencing was performed by the DNA Analysis Core Facility, which is supported by Core Grant CA-16672 from the NCI, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 89, Houston, Texas 77030. Tel.: 713-792-2581; Fax: 713-794-4672; E-mail: kchang@mail.mdanderson.org.

Published, JBC Papers in Press, June 21, 2002, DOI 10.1074/jbc.M201648200

    ABBREVIATIONS

The abbreviations used are: PML, promyelocytic leukemia; APL, acute promyelocytic leukemia; NB, nuclear body; TNFalpha , tumor necrosis factor alpha ; PMA, phorbol 12-myristate 13-acetate; Luc, luciferase; HA, hemagglutinin; PIPES, 1,4-piperazinediethanesulfonic acid; CREB, cAMP-response element-binding protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Mu, Z. M., Chin, K. V., Liu, J. H., Lozano, G., and Chang, K. S. (1994) Mol. Cell. Biol. 14, 6858-6867[Abstract/Free Full Text]
2. Melnick, A., and Licht, J. D. (1999) Blood 93, 3167-3215[Free Full Text]
3. Wang, Z. G., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Gordon-Cardo, C., Grosweld, F., and Pandolfi, P. P. (1998) Science 279, 1547-1551[Abstract/Free Full Text]
4. Le, X. F., Vallian, S., Mu, Z. M., Hung, M. C., and Chang, K. S. (1998) Oncogene 16, 1839-1849[CrossRef][Medline] [Order article via Infotrieve]
5. Mu, Z. M., Le, X. F., Vallian, S., Glassman, A. B., and Chang, K. S. (1997) Carcinogenesis 18, 2063-2069[Abstract/Free Full Text]
6. Wang, Z. G., Ruggero, D., Ronchetti, S., Zhong, S., Gaboli, M., Rivi, R., and Pandolfi, P. P. (1998) Nat. Genet. 20, 266-272[CrossRef][Medline] [Order article via Infotrieve]
7. Quignon, F., De, Bels, F., Koken, M., Feunteun, J., Ameisen, J. C., and de The, H. (1998) Nat. Genet. 20, 259-265[CrossRef][Medline] [Order article via Infotrieve]
8. Liu, J. H., Mu, Z. M., and Chang, K. S. (1995) J. Exp. Med. 181, 1965-1973[Abstract/Free Full Text]
9. Kamitani, T., Kito, K., Nyuyen, H. P., Wada, H., Fukuda-Kamitani, T., and Yeh, E. T. (1998) J. Biol. Chem. 273, 26675-26682[Abstract/Free Full Text]
10. Seeler, J.-S., and Dejean, A. (2001) Oncogene 20, 7243-7249[CrossRef][Medline] [Order article via Infotrieve]
11. Lin, R. J., Sternsdorf, T., Tini, M., and Evans, R. M. (2001) Oncogene 20, 7204-7215[CrossRef][Medline] [Order article via Infotrieve]
12. Zhong, S., Salomoni, P., and Pandolfi, P. P. (2000) Nat. Cell Biol. 2, E85-E90[CrossRef][Medline] [Order article via Infotrieve]
13. LaMorte, V. J., Dyck, J. A., Ochs, R. L., and Evans, R. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4991-4996[Abstract/Free Full Text]
14. Boisvert, F.-M., Kruhlak, M. J., Box, A. K., and Hendzel, M. J. (2001) J. Cell Biol. 152, 1099-1106[Abstract/Free Full Text]
15. Zheng, P., Guo, Y., Niu, Q., Levy, D. E., Dyck, J. A., Lu, S., Sheiman, L. A., and Liu, Y. (1998) Nature 396, 373-376[CrossRef][Medline] [Order article via Infotrieve]
16. Tsuzuki, S., Towatari, M., Saito, H., and Enver, T. (2000) Mol. Cell. Biol. 20, 6276-6286[Abstract/Free Full Text]
17. Vallian, S., Gaken, A. J., Gingold, E. B., Kouzarides, T., Chang, K. S., and Farzaneh, F. (1998) Oncogene 90, 3265-3269
18. Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., Pandolfi, P. P., Will, H., Schneider, C., and DelSal, G. (2000) EMBO J. 22, 6186-6195
19. Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., and Pandolfi, P. P. (2000) Nat. Cell Biol. 2, 730-736[CrossRef][Medline] [Order article via Infotrieve]
20. Pearson, M., and Pelicci, P. G. Oncogene 20, 7250-7256
21. Vallian, S., Gaken, J. A., Trayner, I. D., Gingold, E. B., Kourizarides, T., Chang, K. S., and Farzaneh, F. (1997) Exp. Cell Res. 237, 371-382[CrossRef][Medline] [Order article via Infotrieve]
22. Wu, W. S., Vallian, S., Seto, E., Yang, W. M., Edmondson, D., Roth, S., and Chang, K. S. (2001) Mol. Cell. Biol. 21, 2259-2268[Abstract/Free Full Text]
23. Khan, M. M., Nomura, T., Kim, H., Kaul, S. C., Wadhwa, R., Shinagawa, T., Ichikawa-Iwata, E., Zhong, S., Pandolfi, P. P., and Ishii, S. (2001) Mol. Cell 7, 1233-1243[CrossRef][Medline] [Order article via Infotrieve]
24. Vallian, S., Chin, K. V., and Chang, K. S. (1998) Mol. Cell. Biol. 18, 7147-7156[Abstract/Free Full Text]
25. Opipari, A. W., Boguski, M. S., and Dixit, V. M. (1990) J. Biol. Chem. 265, 14705-14708[Abstract/Free Full Text]
26. Jaattela, M., Mouritzen, H., Elling, F., and Bastholm, L. (1996) J. Immunol. 156, 1166-1173[Abstract]
27. Cooper, J. T., Stroka, D. M., Brostjan, C., Palmetshofer, A., Bach, F. H., and Ferran, C. (1996) J. Biol. Chem. 271, 18068-18073[Abstract/Free Full Text]
28. Ferran, C., Stroka, D. M., Badrichani, A. Z., Cooper, J. T., Wrighton, C. J., Soares, M., Grey, S. T., and Bach, F. H. (1998) Blood 91, 2249-2258[Abstract/Free Full Text]
29. Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M., Lodolce, J. P., and Ma, A. (2000) Science 289, 2350-2354[Abstract/Free Full Text]
30. He, D., Mu, Z.-M., Le, X., Hsieh, J.-T., Pong, R.-C., Chung, L. W. K., and Chang, K. S. (1997) Cancer Res. 57, 1868-1872[Abstract/Free Full Text]
31. Gongora, C., David, G., Pintard, L., Tissot, C., Hua, T. D., Dejean, A., and Mechit, N. (1997) J. Biol. Chem. 272, 19457-19463[Abstract/Free Full Text]
32. Stadler, M., Chelbi-Alix, M. K., Koken, M. H. M., Venturini, L., Lee, C., Saib, A., Quignon, F., Pelicano, L., Guillemin, M. C., Schindler, C., and de The, H. (1995) Oncogene 11, 2565-2573[Medline] [Order article via Infotrieve]
33. Terris, B., Baldin, V., Dubois, S., Degott, C., Flejou, J. F., Henin, D., and Dejean, A. (1995) Cancer Res. 55, 1590-1597[Abstract/Free Full Text]
34. Weinberg, R. A. (1995) Cell 81, 323-330[CrossRef][Medline] [Order article via Infotrieve]
35. Li, H., Leo, C., Zhu, J., Wu, X. Y., O'Neil, J., Park, E. J., and Chen, J. D. (2000) Mol. Cell. Biol. 20, 1784-1796[Abstract/Free Full Text]
36. Lehembre, F., Muller, S., Pandolfi, P. P., and Dejean, A. (2001) Oncogene 20, 1-9[CrossRef][Medline] [Order article via Infotrieve]
37. Zhong, S., Salomoni, P., Ronchetti, S., Guo, A., Ruggero, D., and Pandolfi, P. P. (2000) J. Exp. Med. 191, 631-639[Abstract/Free Full Text]
38. Torii, S., Egan, D. A., Evans, R. A., and Reed, J. C. (1999) EMBO J. 18, 6037-6049[CrossRef][Medline] [Order article via Infotrieve]
39. Beyaert, R., Heyninck, K., and Huffel, S. V. (2000) Biochem. Pharmacol. 60, 1143-1151[CrossRef][Medline] [Order article via Infotrieve]
40. Song, H. Y., Rothe, M., and Goeddel, D. V. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6721-6725[Abstract/Free Full Text]
41. Huffel, V., Delaei, F., Heyninck, K., De, Valck, D., and Beyaert, R. (2001) J. Biol. Chem. 276, 30216-30223[Abstract/Free Full Text]
42. Perkins, N. D. (2000) Trends Biochem. Sci. 25, 434-440[CrossRef][Medline] [Order article via Infotrieve]
43. Rahman, A., Anwar, K. N., True, A. L., and Malik, A. B. (1999) J. Immunol. 162, 5466-5476[Abstract/Free Full Text]
44. Barkett, M., and Gilmore, T. D. (1999) Oncogene 18, 6910-6924[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Cell Biol.Home page
J. Wang, C. Shiels, P. Sasieni, P. J. Wu, S. A. Islam, P. S. Freemont, and D. Sheer
Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions
J. Cell Biol., February 16, 2004; 164(4): 515 - 526.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z.-X. Xu, R.-X. Zhao, T. Ding, T. T. Tran, W. Zhang, P. P. Pandolfi, and K.-S. Chang
Promyelocytic Leukemia Protein 4 Induces Apoptosis by Inhibition of Survivin Expression
J. Biol. Chem., January 16, 2004; 279(3): 1838 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Z.-X. Xu, A. Timanova-Atanasova, R.-X. Zhao, and K.-S. Chang
PML Colocalizes with and Stabilizes the DNA Damage Response Protein TopBP1
Mol. Cell. Biol., June 15, 2003; 23(12): 4247 - 4256.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W.-S. Wu, Z.-X. Xu, W. N. Hittelman, P. Salomoni, P. P. Pandolfi, and K.-S. Chang
Promyelocytic Leukemia Protein Sensitizes Tumor Necrosis Factor alpha -Induced Apoptosis by Inhibiting the NF-kappa B Survival Pathway
J. Biol. Chem., March 28, 2003; 278(14): 12294 - 12304.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/35/31734    most recent
M201648200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, W.-S.
Right arrow Articles by Chang, K.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, W.-S.
Right arrow Articles by Chang, K.-S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.